An Open-Label Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat in Patients With Usher Syndrome Type 1B

Trial Profile

An Open-Label Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat in Patients With Usher Syndrome Type 1B

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs SAR 421869 (Primary)
  • Indications Usher syndromes
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 18 Oct 2017 Planned End Date changed from 1 Apr 2034 to 20 Mar 2035.
    • 18 Oct 2017 Planned primary completion date changed from 1 Apr 2034 to 20 Mar 2035.
    • 15 Mar 2017 Planned End Date changed from 1 Apr 2033 to 1 Apr 2034.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top